Relpax - Worldwide - Overview

Relpax

All Financial Data in US $ (mln)

Worldwide

Overview

Word Search (Top 10 - by date)

PFIZER REPORTS FIRST-QUARTER 2014 RESULTS
Pfizer (May 05, 2014)

Pfizer Reports Fourth-Quarter and Full-Year 2013 Results
Pfizer (January 28, 2014)

Pfizer Reports Third-Quarter 2013 Results
Pfizer (October 29, 2013)

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PuraMed BioScience (August 05, 2013)

Pfizer Reports Second-Quarter 2013 Results
Pfizer (July 30, 2013)

Displaying 10 out of a possible 81 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product:	Relpax
Generic Name:	eletriptan hydrobromide
Therapeutic Subcategory:	Anti-migraine preparations

Product Sales Summary 2010/11

				Annual Sales WW - Sales		Growth per Year (%)
	Rank¹	Generic Name	Therapeutic Subcategory	2010	2011	2011
Relpax²				323	341	+6%
	Note: Shaded Cells³

Clinical Trial Coverage: No. of Trials involving Product

	Trial Count
Relpax⁴	21

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate

Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

2011 Product Sales analysis
Download analysis into Excel
Search 2 yrs of company press releases

Research Codes Synonyms

Product:

Relpax

Ranked on:
Annual Sales WW
2011

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.